SLShan Lyu

Shan Lyu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shan Lyu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Jie Li

    Division of Respiratory Care, Department of Cardiopulmonary Sciences, Rush University, Chicago, IL

    2 shared publications
  • Binhai Pan

    Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing, China

    1 shared publication
  • Dehua He

    Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Beijing Road No. 8, Yunyan District, Guiyang, Guizhou Province, 550001, China, 86 13511999117

    1 shared publication
  • Fang Ni

    Department of Respiratory and Critical Care Medicine, The Central Hospital of Wuhan, Wuhan, China

    1 shared publication
  • Guanghan Wu

    Department of Critical Care Medicine, People's Hospital of Jianghua Yao Autonomous County, Yongzhou, China

    1 shared publication
  • Guilan Zeng

    Department of Critical Care Medicine, Zhangzhou Hospital Traditional Chinese Medicine, Zhangzhou, China

    1 shared publication

Latest Publications

  • Inhaled Antibiotics to Treat Ventilator-Associated Pneumonia: A Systematic Review and Meta-Analysis

    by Shan Lyu, Jian Luo, Ping Bs Liu, Xiaojing Qin, Wanjia He, Guoqiang Jing, Stephan Ehrmann, Jie Li

    OBJECTIVES: To assess the effects of adjunctive inhaled antibiotics in treating ventilator-associated pneumonia (VAP). DATA SOURCES: We searched PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov through May 31, 2025. STUDY SELECTION: We included randomized controlled trials (RCTs) and nonrandomized studies comparing adjunctive inhaled antibiotics with placebo/blank or IV antibiotics for VAP treatment. DATA EXTRACTION: Two groups independently screened studies, extracted data, and assessed risk of bias. Analyses used random effects models. Subgroup analyses, meta-regression, trial sequential analysis, and the Grading of Recommendations Assessment, Development, and Evaluation were performed. DATA SYNTHESIS: We included 32 RCTs in the primary analysis and 41 non-RCTs in sensitivity analysis. Compared with placebo/blank, inhaled antibiotics significantly improved clinical cure (16 RCTs; n = 1425; risk ratio [RR], 1.24; 95% CI, 1.07–1.43) and reduced all-cause mortality (21 RCTs; n = 1855; RR, 0.84; 95% CI, 0.71–0.98), with consistent findings in sensitivity analyses including non-RCTs. These benefits were significant in VAP-only patients (clinical cure: 11 RCTs; n = 775; RR, 1.29; 95% CI, 1.10–1.52 and all-cause mortality: 15 RCTs; n = 1152; RR, 0.77; 95% CI, 0.65–0.90), but not in studies including mixed pneumonia populations. Meta-regression confirmed VAP-only population as a significant effect modifier. Inhaled antibiotics also improved microbiological eradication (20 RCTs; n = 1805; RR, 1.42; 95% CI, 1.27–1.58) and reduced emergence of new drug resistance (four RCTs; n = 182; RR, 0.20; 95% CI, 0.06–0.64). No differences were found in ICU length of stay, ventilator duration, or other adverse events. Compared with IV antibiotics, inhaled antibiotics shortened ventilator duration (three RCTs; n = 322; mean difference, –2.11 d; 95% CI, –3.73 to –0.49 d), and reduced nephrotoxicity (three RCTs; n = 292; RR, 0.42; 95% CI, 0.26–0.68). CONCLUSIONS: Compared with placebo/blank, adjunctive inhaled antibiotics improve clinical cure and microbiological eradication, and may reduce mortality, particularly in VAP-only patients. Exploratory analyses based on limited data suggest potential advantages over IV therapy, including shorter ventilator duration and lower nephrotoxicity, warranting further high-quality trials.


  • The Use of Aerosolized Medications in Adult Intensive Care Unit Patients: A Prospective, Multicenter, Observational, Cohort Study

    by Shan Lyu, Jie Li, Mengmeng Wu, Dehua He, Tinggan Fu, Fang Ni, Xu Tan, Guanghan Wu, Binhai Pan, Liucun Li, et al.

    Background: Only limited data are available on the real-life clinical utilization of aerosolized medications in intensive care unit (ICU) patients. Exploring the utilization of aerosolized medications in the ICU may contribute to develop appropriate education and improve the quality of aerosol therapy. Methods: A 2-week, prospective, multicenter, observational, cohort study was conducted to record how the aerosolized medications were utilized in the Chinese ICUs, including indications, medications used in solo or combination, dosage, and side-effects in adult patients. Results: A total of 1006 patients from 28 ICUs were enrolled, of which 389 (38.7%) received aerosol therapy. The most common indications for aerosol therapy were difficulty in secretion management (23.1%) and chronic obstructive pulmonary disease exacerbation (18.5%). The combination of inhaled corticosteroids and short-acting muscarinic antagonist was the most commonly used medication (19.5%, 76/389). Ninety-two percent (358/389) of the patients did not have any side effects during aerosol therapy. More patients in the group with mechanical ventilation received bronchodilators than spontaneous breathing patients (81.3% vs. 55.5%, p < 0.001), and more patients who breathed spontaneously through a tracheostomy received mucus-regulating agents than other patients (70% vs. 37.9%, p = 0.004). Conclusion: In mainland China, more than one-third of adult ICU patients received aerosol therapy. Medications utilized during aerosol therapy were variable in patients with different respiratory support. To promote appropriate use of aerosolized medications, high-quality randomized, controlled trials and clinical guidance on aerosolized medication indications and dosing are needed to improve clinical outcomes.